Tim Preijers

Improving the tolerability of osimertinib by identifying its toxic limit

Bram C. Agema, G. Veerman, C. Steendam et al. · Therapeutic Advances in Medical Oncology · 2022 · 36 citations · Full text

Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII

Tim Preijers, Iris van Moort, Karin Fijnvandraat et al. · Thrombosis and Haemostasis · 2018 · 22 citations

In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients

Tim Preijers, H.C.A.M. Hazendonk, Karin Fijnvandraat et al. · Journal of Thrombosis and Haemostasis · 2017 · 15 citations · Full text

Thrombosis, Silico Evaluation, Hemophilia B Patients +10

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

Iris van Moort, Tim Preijers, Laura H. Bukkems et al. · The Lancet Haematology · 2021 · 13 citations · Full text

Thrombosis, Hematology, Hemostasis +6

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery

Tim Preijers, H.C.A.M. Hazendonk, Ri Liesner et al. · Journal of Thrombosis and Haemostasis · 2018 · 12 citations · Full text